Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT06267924
Other study ID # Olith10703
Secondary ID
Status Enrolling by invitation
Phase N/A
First received
Last updated
Start date February 28, 2024
Est. completion date September 30, 2024

Study information

Verified date March 2024
Source Otolith Labs
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this virtual clinical trial is to compare the effectiveness of two study devices in providing temporary relief to adults aged 18-75 who suffer from symptoms of chronic Vestibular Migraines (VM), also known as Migraine Associated Vertigo. Participants will be: - Enrolled up to 50 days; enrollment, 14 days in Baseline Phase (no device), 7 days in Transition Phase, 28 days in Treatment Phase (study device) - Randomized and stratified into groups based on the referring clinic to be assigned one study device - Asked to use the study device as instructed by the study coordinator - Asked to submit daily diaries reporting their symptoms and use of device, and to participate in tele-health visits with study coordinators - Asked to provide their vertigo diagnosis from their physician - Compensated for their participation Researchers will compare the randomized groups to determine which group responds better to which device.


Description:

This study is a decentralized clinical trial. This study uses technology and virtual meetings to communicate with study participants and collect study data. This study seeks to enroll until 200 participants have completed the study per protocol. Study participants that meet all of the inclusion, none of the exclusion criteria, and sign informed consent will be enrolled in the study. Participants will complete a one day enrollment meeting and a 14 day Baseline Phase. If a participant is eligible to remain in the study for the Treatment Phase at day 15, they will be randomized within their assigned group at a 1:1 ratio to an Active arm or Sham arm to begin the Treatment Phase of the study. Participants will be sent a study device to use when they have a vertigo episode. Participants that enroll in the study are expected to participate up to 50 days with virtual meetings at the approximate intervals: Day 15, Day 22, Day 25, Day 35, and Day 50 Participants will be required to complete the DHI (Dizziness Handicap Inventory), VM-PATHI (Vestibular Migraine Patient Assessment Tool and Handicap Inventory), General Vertigo History, Global Impression of Change, "Most Bothersome Symptom", Relief from "Most Bothersome Symptom", and Net promoter score questionnaires. Otolith Labs received Therapeutic Breakthrough Device designation by the FDA in May, 2021.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 200
Est. completion date September 30, 2024
Est. primary completion date August 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: To be eligible to participate in this study, an individual must meet all the following criteria: - Diagnosed as having Vestibular Migraine (VM) (aka Migraine Associated Vertigo) The participant's diagnosis must be provided by a physician, Board certified in Otolaryngology or Neurology, from one of the study's approved clinics. Diagnosis for VM must follow Bárány Society's "International Classification of Vestibular Disorders", which contains the Society's consensus diagnostic criteria for VM [Lempert 2022, sect. 3]. - Male or female subjects, age 18 to 75 years old inclusive on day of enrollment - Residing in the United States - Vestibular migraines that have been recurrent for at least 90 days - Score from 36 to 90 inclusive on the Dizziness Handicap Inventory (DHI) (corresponding to moderate to severe vertigo) - A smartphone, computer or tablet and access to internet to complete study procedures and study meetings - Willing and able to comply with study procedures - Willingness to use Venmo or Paypal for study stipend Exclusion Criteria: - Females who are pregnant or trying to become pregnant - Enrolled in previous Otolith Lab-sponsored clinical trial - Currently taking part in another interventional trial - Surgery to the skull base within the last 6 months or plans for surgery to the skull during enrollment period - Skull or neck implants - History of vitreous detachment in the last 90 days - Superior canal dehiscence or otic capsule dehiscence - Diagnosed hyperacusis - Undergoing vestibular rehabilitation therapy or planning to start vestibular rehabilitation therapy during the study - History of cerebrovascular disorders - Posterior fossa tumors, vestibular schwannoma - Cerebellar degeneration (progressive worsening of neurons behind the brain stem) - Taking benzodiazepines (e.g., clonazepam, lorazepam, diazepam) - Initiation of calcitonin gene-related peptide inhibitor treatment within 4 weeks prior to beginning of trial - Cognitive impairment or inability to follow study procedures

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Otoband Experimental
Participants will be randomly assigned to use the Otoband to determine effectiveness in providing temporary relief to symptoms of vertigo.
Otoband Sham
Participants will be randomly assigned to use the Otoband sham to determine effectiveness in providing temporary relief to symptoms of vertigo.

Locations

Country Name City State
United States Otolith Labs Washington District of Columbia

Sponsors (2)

Lead Sponsor Collaborator
Otolith Labs MCRA

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary DHI Change in Scores Reduction in final "Dizziness Handicap Inventory" (DHI) score by at least 12 points, compared to transition DHI score Day 23 - Day 51
Secondary Number of related adverse events Assessment of any related adverse events and device usage Day 23 - Day 51
Secondary Change in number of vestibular migraine episodes weekly Assessment of the number of vestibular migraine episodes each week Day 1 - Day 51
Secondary Global Impression of Change (severity of episodes) Assessment of the results of Global Impression of Change questionnaire and impacts on the severity of episodes Day 51
Secondary DHI change from transition to end of study Assessment of overall changes in DHI score from transition time point to the end of the study Day 23 - Day 51
Secondary Device responder rate Assessment of the responder rate of the study arms and their device usage Day 23 - Day 51
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT04196933 - Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma N/A
Recruiting NCT04417361 - Galcanezumab for Vestibular Migraine Phase 2
Enrolling by invitation NCT05396482 - Assesment of Hearing in Patients With Vestibular Migra
Completed NCT03979677 - Effects of Lifestyle Modification on Vestibular Migraine N/A
Completed NCT05157399 - Quantification of the Effect of the OtoBand on Objective Measures of Vertigo and Dizziness N/A
Not yet recruiting NCT05914207 - Non-Pharmacological Treatment of Vestibular Migraine in Children and Adolescent N/A
Enrolling by invitation NCT06417684 - Comparison of Amitriptyline to Lifestyle Modification as Intervention for Vestibular Migraine Early Phase 1
Recruiting NCT04939922 - China Headache Registry Study
Recruiting NCT05472675 - Local Sensory Nerve Block in the Treatment of Vestibular Migraine N/A
Recruiting NCT05418218 - International Headache Registry Study
Suspended NCT04026516 - CAVA: Dizziness Trial N/A
Withdrawn NCT03578354 - 4-Aminopyridine, Atenolol, or Placebo in Patients With Vestibular Migraine Phase 2
Completed NCT02350985 - Comparison of Propranolol and Venlafaxine in Treatment of Vestibular Migraine Phase 4
Completed NCT03417596 - Vestibular Rehabilitation in Patients With Vestibular Migraine N/A
Not yet recruiting NCT04664088 - Acupuncture for Prophylaxis of Vestibular Migraine N/A
Completed NCT05960786 - Treating the Symptoms of Vertigo in a Real-world Setting Using the OtoBand N/A
Completed NCT02447991 - Rizatriptan for Episodic Dizziness in Vestibular Migraine Phase 2/Phase 3
Recruiting NCT04935970 - Metabolic Disorders and Vertigo
Not yet recruiting NCT05508139 - The Role Of Vestibular Rehabilitation Therapy In Management Of Vestibular Migraine Patients
Completed NCT01669304 - Verapamil vs. Sertraline for Vestibular Migraine & Chronic Subjective Dizziness Phase 1